#Liechtenstein #Vaduz #Capital Markets Day #Implantica #RefluxStop

Implantica's Capital Markets Day Webcast

Implantica AG, a leader in medtech innovation, held its Capital Markets Day on September 9, 2026, in Stockholm. The company expressed gratitude to attendees and announced that the entire event is now available for viewing online. This presentation focuses on Implantica's strategic rollout of its groundbreaking RefluxStop® device in the U.S. following its recent FDA approval.

Key Highlights from the Event

The webcast provides comprehensive insights, featuring discussions by leading surgeons on the RefluxStop® device and the nuanced issues surrounding acid reflux treatment. Among the standout moments were testimonials from patients, including a surgeon who is a RefluxStop® recipient himself. This event was not just a corporate presentation but an engaging platform for sharing knowledge and experiences regarding the future of gastroesophageal reflux disease (GERD) treatment.

Structured for Easy Navigation

For viewers looking for particular segments, the video is divided into chapters. Each chapter can be accessed directly, making it easy for viewers to focus on areas of interest. Key segments include:

• - Welcome by Tomas Puusepp, Board Member
• - CEO Update on Vision and Strategy by Dr. Peter Forsell, CEO & Founder
• - Market Opportunities in the U.S. by Amit Kukreja, COO & President, U.S. Operations
• - Marketing Strategies shared by Juanita Eberhart, VP Marketing & Advocacy
• - Clinical Insights presented by Dr. John C. Lipham from the University of Southern California
• - Patient Stories and Perspectives, highlighting real-world experiences with RefluxStop®
• - Panel Discussions featuring multiple experts discussing their collective insights and answering audience questions

About RefluxStop®

RefluxStop® represents a significant advancement in the treatment of GERD, addressing the condition at its core rather than through conventional methods that may cause unpleasant side effects. Unlike traditional surgeries, RefluxStop is designed to restore the lower esophageal sphincter’s natural function without encasing or constricting it. This innovative approach significantly reduces complications often associated with anti-reflux procedures.

The empirical evidence supporting RefluxStop® is robust, with long-term clinical outcomes demonstrating its effectiveness in providing meaningful relief to a considerable portion of the GERD patient population. Studies have shown that the device can have a lasting positive impact on quality of life, making it a promising option for individuals suffering from this chronic condition.

Future Developments

Implantica continues to invest in advanced technologies, with future innovations on the horizon. The company is not only focused on the RefluxStop® implant but also on integrating eHealth platforms that would facilitate real-time communication and remote monitoring of these implants, heralding a new era of patient management in medtech.

As Implantica prepares for its wider market launch, the company’s dedication to improving patient outcomes remains paramount, making it an essential player in the healthcare landscape.

Conclusion

For those who missed the live event, the Capital Markets Day webcast is a must-watch for both investors and industry professionals eager to gain insights into Implantica’s future trajectory and the potential impact of its cutting-edge medical technology. Visit here to watch the full presentation and explore the entry points into the transformative world of GERD treatment with RefluxStop®.